Skip to main content
Erschienen in: International Journal of Clinical Oncology 7/2019

23.02.2019 | Original Article

Analysis of major BCR-ABL1 mRNA by digital polymerase chain reaction is useful for prediction of international scale

verfasst von: Daisuke Furuya, Mikako Moriai, Yuki Koizumi, Teruo Endo, Kouichi Asanuma, Nozomi Yanagihara, Satoshi Takahashi

Erschienen in: International Journal of Clinical Oncology | Ausgabe 7/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

Major BCR-ABL1 mRNA in patients with chronic myeloid leukemia (CML) has generally been analysed by real-time polymerase chain reaction (PCR). Application of the international scale (IS) for the quantification of major BCR-ABL1 mRNA has been recommended in several sets of guidelines, including those of the European LeukemiaNet. The aim of this study was to clarify the efficacy of digital PCR technology for the IS of BCR-ABL1 mRNA in the patients with CML by comparing with real-time PCR.

Methods

The analysis of BCR-ABL1 mRNA was carried out by the Ipsogen® BCR-ABL1 Mbcr IS-MMR DX Kit (Qiagen), and the QuantStudio 3D Digital PCR System (Thermo Fisher Scientific‎) using 20 peripheral blood samples obtained from the 9 patients with CML at Sapporo Medical University Hospital.

Results

The correlation between the data obtained by digital PCR and by real-time PCR was really high at R = 0.96. The detection limit of digital PCR was up to 0.003% and was equal to IS with 0.01% or less in comparison with real-time PCR.

Conclusions

Digital PCR technology is promising for predicting the IS value with similar efficacy to real-time PCR and should be useful for simple monitoring of the effects of tyrosine kinase inhibitor (TKI) treatments.
Literatur
1.
Zurück zum Zitat Gabert J, Beillard E, van der Velden VH et al (2003) Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 17:2318–2357CrossRefPubMed Gabert J, Beillard E, van der Velden VH et al (2003) Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 17:2318–2357CrossRefPubMed
2.
Zurück zum Zitat Hughes T, Deininger M, Hochhaus A et al (2006) Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 108:28–37CrossRefPubMedPubMedCentral Hughes T, Deininger M, Hochhaus A et al (2006) Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 108:28–37CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Baccarani M, Deininger MW, Rosti G et al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122:872–884CrossRefPubMedPubMedCentral Baccarani M, Deininger MW, Rosti G et al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122:872–884CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Usui N (2017) JSH guideline for tumors of hematopoietic and lymphoid tissues-leukemia: 4. Chronic myelogenous leukemia (CML)/myeloproliferative neoplasms (MPN). Int J Hematol 106:591–611CrossRefPubMed Usui N (2017) JSH guideline for tumors of hematopoietic and lymphoid tissues-leukemia: 4. Chronic myelogenous leukemia (CML)/myeloproliferative neoplasms (MPN). Int J Hematol 106:591–611CrossRefPubMed
6.
Zurück zum Zitat Cross NC, Hochhaus A, Müller MC (2015) Molecular monitoring of chronic myeloid leukemia: principles and interlaboratory standardization. Ann Hematol 94:S219–S225CrossRefPubMed Cross NC, Hochhaus A, Müller MC (2015) Molecular monitoring of chronic myeloid leukemia: principles and interlaboratory standardization. Ann Hematol 94:S219–S225CrossRefPubMed
7.
Zurück zum Zitat Hindson CM, Chevillet JR, Briggs HA et al (2013) Absolute quantification by droplet digital PCR versus analog real-time PCR. Nat Methods 10:1003–1005CrossRefPubMedPubMedCentral Hindson CM, Chevillet JR, Briggs HA et al (2013) Absolute quantification by droplet digital PCR versus analog real-time PCR. Nat Methods 10:1003–1005CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Koizumi Y, Furuya D, Endo T et al (2018) Quantification of Wilms’ tumor 1 mRNA by digital polymerase chain reaction. Int J Hematol 107:230–234CrossRefPubMed Koizumi Y, Furuya D, Endo T et al (2018) Quantification of Wilms’ tumor 1 mRNA by digital polymerase chain reaction. Int J Hematol 107:230–234CrossRefPubMed
9.
Zurück zum Zitat Goh HG, Lin M, Fukushima T et al (2011) Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay. Leuk Lymphoma 52:896–904CrossRefPubMed Goh HG, Lin M, Fukushima T et al (2011) Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay. Leuk Lymphoma 52:896–904CrossRefPubMed
10.
Zurück zum Zitat Jennings LJ, George D, Czech J et al (2014) Detection and quantification of BCR-ABL1 fusion transcripts by droplet digital PCR. J Mol Diagn 16:174–179CrossRefPubMed Jennings LJ, George D, Czech J et al (2014) Detection and quantification of BCR-ABL1 fusion transcripts by droplet digital PCR. J Mol Diagn 16:174–179CrossRefPubMed
11.
Zurück zum Zitat Iacobucci I, Lonetti A, Venturi C et al (2014) Use of a high sensitive nanofluidic array for the detection of rare copies of BCR-ABL1 transcript in patients with Philadelphia-positive acute lymphoblastic leukemia in complete response. Leuk Res 38:581–585CrossRefPubMed Iacobucci I, Lonetti A, Venturi C et al (2014) Use of a high sensitive nanofluidic array for the detection of rare copies of BCR-ABL1 transcript in patients with Philadelphia-positive acute lymphoblastic leukemia in complete response. Leuk Res 38:581–585CrossRefPubMed
12.
Zurück zum Zitat Alikian M, Whale AS, Akiki S et al (2017) RT-qPCR and RT-digital PCR: a comparison of different platforms for the evaluation of residual disease in chronic myeloid leukemia. Clin Chem 63:525–531CrossRefPubMed Alikian M, Whale AS, Akiki S et al (2017) RT-qPCR and RT-digital PCR: a comparison of different platforms for the evaluation of residual disease in chronic myeloid leukemia. Clin Chem 63:525–531CrossRefPubMed
13.
Zurück zum Zitat Whelan JA, Russel NB, Whelan MA (2003) A method for the absolute quantification of cDNA using real time PCR. J Immunol Methods 278:261–269CrossRefPubMed Whelan JA, Russel NB, Whelan MA (2003) A method for the absolute quantification of cDNA using real time PCR. J Immunol Methods 278:261–269CrossRefPubMed
14.
Zurück zum Zitat Soverini S, De Benedittis C, Mancini M et al (2016) Best practices in chronic myeloid leukemia monitoring and management. Oncologist 21:626–633CrossRefPubMedPubMedCentral Soverini S, De Benedittis C, Mancini M et al (2016) Best practices in chronic myeloid leukemia monitoring and management. Oncologist 21:626–633CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Takahashi N, Tauchi T, Kitamura K et al (2018) Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study. Int J Hematol 107:185–193CrossRefPubMed Takahashi N, Tauchi T, Kitamura K et al (2018) Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study. Int J Hematol 107:185–193CrossRefPubMed
Metadaten
Titel
Analysis of major BCR-ABL1 mRNA by digital polymerase chain reaction is useful for prediction of international scale
verfasst von
Daisuke Furuya
Mikako Moriai
Yuki Koizumi
Teruo Endo
Kouichi Asanuma
Nozomi Yanagihara
Satoshi Takahashi
Publikationsdatum
23.02.2019
Verlag
Springer Singapore
Erschienen in
International Journal of Clinical Oncology / Ausgabe 7/2019
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-019-01419-9

Weitere Artikel der Ausgabe 7/2019

International Journal of Clinical Oncology 7/2019 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.